Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bioage LabsFRA:Y7G -7.17%12 Quick Ratio is 17.19 as of Jun. 2026, which is 32% above its 10-year median of 13.04. GuruFocus rates FRA:Y7G with a GF Score™ of 12/100. The stock has 3 warning signs investors should review. Among 996 Drug Manufacturers companies, Bioage Labs ranks better than 97.69% on this metric.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Bioage Labs's quick ratio for the quarter that ended in Jun. 2026 was 17.19.
Bioage Labs has a quick ratio of 17.19. It generally indicates good short-term financial strength.
The historical rank and industry rank for Bioage Labs's Quick Ratio or its related term are showing as below:
FRA:Y7G'
s Quick Ratio Range Over the Past 10 Years
Min: 0.44 Med: 13.04 Max: 24.76
Current: 17.19
During the past 4 years, Bioage Labs's highest Quick Ratio was 24.76. The lowest was 0.44. And the median was 13.04.
FRA:Y7G's Quick Ratio is ranked better than 97.69% of 996
companies
in the Drug Manufacturers industry
Industry Median: 1.42
vs FRA:Y7G: 17.19
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Bioage Labs Quick Ratio Related Terms
Bioage Labs Quick Ratio Historical Data
* Premium members only.
The historical data trend for Bioage Labs's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:Y7G vs PCRX, ALVO, AMPH: Quick Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Bioage Labs's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bioage Labs Quick Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bioage Labs's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Bioage Labs's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Bioage Labs's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bioage Labs (FRA:Y7G) has a Quick Ratio of 17.19 as of Jun. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Bioage Labs and its competitors. This is 32% above median its historical median of 13.04. Over the past decade, Bioage Labs' Quick Ratio has ranged from 0.44 to 24.76. According to the industry distribution chart, Bioage Labs ranks #23 out of 996 companies in the Drug Manufacturers industry, placing it in the top 2.3%.
Is Bioage Labs' Quick Ratio too high?
Bioage Labs' current Quick Ratio of 17.19 is 32% above median its 10-year median of 13.04. Over the past 10 years, this metric has ranged from a low of 0.44 to a high of 24.76. The Drug Manufacturers industry median Quick Ratio is 1.42. Bioage Labs' value of 17.19 is 1110.6% above this industry median. Based on the distribution chart, Bioage Labs ranks #23 out of 996 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Bioage Labs has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Bioage Labs' Quick Ratio compare to PCRX and ALVO?
According to the Drug Manufacturers industry distribution chart, Bioage Labs ranks #23 out of 996 companies for Quick Ratio. This places Bioage Labs in the top 2% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 1.42. Bioage Labs' value of 17.19 is 1110.6% above this benchmark. Historically, Bioage Labs' own Quick Ratio has ranged from 0.44 to 24.76 over the past decade. While the company's 10-year median is 13.04 vs. the industry median of 1.42, Bioage Labs has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Drug Manufacturers company?
The median Quick Ratio among Drug Manufacturers companies is 1.42, based on 996 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bioage Labs's current Quick Ratio of 17.19 is 1110.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Bioage Labs and its competitors. For the Drug Manufacturers industry, the median Quick Ratio is 1.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bioage Labs's current Quick Ratio is 17.19, which is 32% above median its own 10-year median of 13.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioage Labs stock overvalued right now?
Bioage Labs (FRA:Y7G) has a current Quick Ratio of 17.19. The current Quick Ratio is 17.19, which is 32% above median its 10-year median of 13.04 and 1110.6% above the Drug Manufacturers industry median of 1.42. Bioage Labs' overall GF Score™ is 12/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Bioage Labs (FRA:Y7G), the current Quick Ratio is 17.19 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. The company's technology platform and differentiated human datasets enable the identification of targets based on insights into molecular changes that drive aging. The Company operates and manages its business as one reportable and operating segment, which is the business of extending healthy human life by targeting molecular causes of aging.
12GF Score
Get the complete analysis for FRA:Y7G
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:Y7G has been successfully added to your 
